Business
Nexalin Technology Announces Issuance of U.S. Patent Covering HALO™ Clarity Device Featuring DIFS™ Technology
HOUSTON, TX, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Design Patent No. D1,092,758, entitled Transcranial Electro-Stimulation Device, providing 15 years of design protection for the Company’s next-generation HALO™ Clarity neuromodulation device. HALO™ Clarity is
About this update from Nexalin Technology, Inc.
[{"type":"image","alt":"Nexalin Technology, Inc.","displaySize":"","headline":null,"caption":"Nexalin Technology, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":200,"height":200,"url":"https://media.zenfs.com/en/globenewswire.com/5068cf7d0dc54dda72cad25cf178ec76"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/kPm7LNc3A4iAJ.KL_fneQQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTM2MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5068cf7d0dc54dda72cad25cf178ec76","width":200,"height":200}},"lazy":false},{"type":"text","content":"HOUSTON, TX, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Design Patent No. D1,092,758, entitled Transcranial Electro-Stimulation Device, providing 15 years of design protection for the Company’s next-generation HALO™ Clarity neuromodulation device.","length":482,"tagName":"p"},{"type":"text","content":"HALO™ Clarity is designed to deliver non-invasive neuromodulation by stimulating deep brain structures associated with mental health and neurological conditions, such as Alzheimer’s, without reliance on pharmaceuticals or surgery. The newly issued patent strengthens Nexalin’s expanding intellectual property estate, supporting the Company’s DIFS™ platform and ongoing clinical and regulatory initiatives.","length":405,"tagName":"p"},{"type":"text","content":"“This patent represents another important milestone in our mission to transform mental health and neurological care,” said Mark White, Chief Executive Officer of Nexalin. “HALO™ Clarity is engineered for comfort, usability, and performance to deliver our proprietary DIFS™ technology — a non-invasive, drug-free approach we believe can meaningfully impact conditions such as depression, anxiety, insomnia, trauma-related disorders, and neurodegenerative diseases including Alzheimer’s and dementia. Importantly, the system is designed for supervised use from the patient’s home, giving physicians the ability to monitor and guide treatment remotely while offering patients a safe and convenient alternative to in-clinic visits. We believe this unique capability has the potential to expand access, improve compliance, and lower the...